Department of Molecular and Translational Medicine (MTM), Texas Tech University Health Science Center El Paso, 5001 El Paso Drive, El Paso, TX, 79905, USA.
Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, 79902, USA.
Cell Commun Signal. 2022 Aug 15;20(1):120. doi: 10.1186/s12964-022-00926-z.
Breast cancer, the most diagnosed cancer, remains the second leading cause of cancer death in the United States, and excessive Progesterone (PRG) or Mifepristone (MIF) exposure may be at an increased risk for developing breast cancer. PRG exerts its cellular responses through signaling cascades involving classic, non-classic, or combined responses by binding to either classic nuclear PRG receptors (nPRs) or non-classic membrane PRG receptors (mPRs). Currently, the intricate balance and switch mechanisms between these two signaling cascades remain elusive. Three genes, CCM1-3, form the CCM signaling complex (CSC) which mediates multiple signaling cascades.
Utilizing molecular, cellular, Omics, and systems biology approaches, we analyzed the relationship among the CSC, PRG, and nPRs/mPRs during breast cancer tumorigenesis.
We discovered that the CSC plays an essential role in coupling both classic and non-classic PRG signaling pathways by mediating crosstalk between them, forming the CmPn (CSC-mPRs-PRG-nPRs) signaling network. We found that mPR-specific PRG actions (PRG + MIF) play an essential role in this CmPn network during breast cancer tumorigenesis. Additionally, we have identified 4 categories of candidate biomarkers (9 intrinsic, 2 PRG-inducible, 1 PRG-repressive, 1 mPR-specific PRG-repressive, and 2 mPR-responsive) for Luminal-A breast cancers during tumorigenesis and have confirmed the prognostic application of RPL13 and RPL38 as intrinsic biomarkers using a dual validation method.
We have discovered that the CSC plays an essential role in the CmPn signaling network for Luminal-A breast cancers with identification of two intrinsic biomarkers. Video Abstract.
乳腺癌是美国最常见的癌症,也是癌症死亡的第二大主要原因,孕激素(PRG)或米非司酮(MIF)暴露过量可能会增加患乳腺癌的风险。PRG 通过经典、非经典或联合反应与经典核 PRG 受体(nPRs)或非经典膜 PRG 受体(mPRs)结合,发挥其细胞反应。目前,这两种信号转导途径之间的复杂平衡和转换机制仍难以捉摸。三个基因,即 CCM1-3,形成 CCM 信号复合物(CSC),介导多种信号转导途径。
利用分子、细胞、组学和系统生物学方法,我们分析了 CSC、PRG 和 nPRs/mPRs 之间在乳腺癌肿瘤发生过程中的关系。
我们发现 CSC 通过介导它们之间的串扰,在经典和非经典 PRG 信号通路之间发挥关键作用,形成 CmPn(CSC-mPRs-PRG-nPRs)信号网络。我们发现 mPR 特异性 PRG 作用(PRG+MIF)在乳腺癌肿瘤发生过程中在这个 CmPn 网络中起着至关重要的作用。此外,我们已经确定了 4 类候选生物标志物(9 种内在的、2 种 PRG 诱导的、1 种 PRG 抑制的、1 种 mPR 特异性 PRG 抑制的和 2 种 mPR 响应的)用于 Luminal-A 乳腺癌在肿瘤发生过程中,并通过双重验证方法证实了 RPL13 和 RPL38 作为内在生物标志物的预后应用。
我们发现 CSC 在 Luminal-A 乳腺癌的 CmPn 信号网络中起着关键作用,并确定了两个内在的生物标志物。视频摘要。